Fidelity Digital Assets reports that companies issuing perpetual preferred stock have financed the purchase of 135,979 Bitcoin as of October 5. This funding model relies on Bitcoin's price gains outpacing the cost of dividend payments to preferred shareholders. The strategy represents over 0.5% of Bitcoin's maximum supply and highlights a growing trend where firms raise capital through preferred shares to invest in Bitcoin, betting on its limited supply to preserve value against fiat inflation. However, preferred shareholders face risks including issuer credit risk, liquidity issues, and sensitivity to interest rates, making this a complex investment tied to both Bitcoin's performance and the issuing companies' financial health.
Fidelity's report on preferred stock funding Bitcoin purchases provides context for cryptocurrency trends. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 21, 2026 02:31 WIB: 44 of 50 major cryptocurrencies rose today. Notable movers include Basic Attention Token at Rp3.648 (+10.08%), EOS.IO at Rp12.649 (+8.13%), and COTI at Rp201 (+5.44%).
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
